Branded

AstraZeneca intros Airsupra

Airsupra (albuterol/budesonide) is the first and only FDA-approved anti-inflammatory rescue option for asthma.
Octapharma intros Balfaxar

Balfaxar is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients.
Johnson & Johnson to acquire Ambrx Biopharma

The acquisition will advance next generation antibody drug conjugates to transform the treatment of cancer.
FDA approves expanded use of Astella's Cresemba

Cresemba is the only azole antifungal therapy approved for pediatric patients affected by these serious, potentially life-threatening infections.
Amneal, BIAL ink U.S. licensing agreement for Ongentys

Ongentys (opicapone) is an adjunctive therapy for the treatment of Parkinson’s disease.
Takeda launches Adzynma

Adzynma is the first recombinant ADAMTS13 enzyme replacement therapy for treating Congenital Thrombotic Thrombocytopenic Purpura.
Novo Nordisk sues 2 Florida pharmacies for allegedly selling impure weight-loss drugs

Novo Nordisk's lawsuits allege that the pharmacies' products claiming to contain the active ingredient for its in-demand weight-loss drug Wegovy were impure.
Pfizer, Astellas obtain FDA OK for Xtandi

Xtandi is the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer.

Gilead’s Biktarvy receives FDA OK for expanded indication